compared with or without trastuzumab in treating women with ductal carcinoma in situ who
have undergone lumpectomy. Monoclonal antibodies, such as trastuzumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Radiation
therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether radiation
therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.